Supernus to Participate in Two Upcoming Investor Conferences
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in upcoming March investor conferences. Jack Khattar, President and CEO, will represent the company at these events.
The company will feature a fireside chat at the Barclays Global Healthcare Conference, which will be available via live audio webcast. Investors can access the webcast through the Events & Presentations section of Supernus's website at www.supernus.com. The webcast recording will remain accessible for 60 days following the conference.
Interested investors seeking meetings with Supernus management during these conferences should reach out to the respective conference coordinators for arrangements.
Supernus Pharmaceuticals (Nasdaq: SUPN), un'azienda biofarmaceutica specializzata nelle malattie del sistema nervoso centrale (CNS), ha annunciato la sua partecipazione a prossimi conferenze per investitori a marzo. Jack Khattar, Presidente e CEO, rappresenterà l'azienda in questi eventi.
L'azienda presenterà un incontro informale al Barclays Global Healthcare Conference, che sarà disponibile tramite webcast audio dal vivo. Gli investitori possono accedere al webcast attraverso la sezione Eventi & Presentazioni del sito web di Supernus all'indirizzo www.supernus.com. La registrazione del webcast rimarrà accessibile per 60 giorni dopo la conferenza.
Gli investitori interessati a incontri con la direzione di Supernus durante queste conferenze dovrebbero contattare i coordinatori delle rispettive conferenze per organizzare gli appuntamenti.
Supernus Pharmaceuticals (Nasdaq: SUPN), una empresa biofarmacéutica especializada en enfermedades del sistema nervioso central (CNS), ha anunciado su participación en próximas conferencias para inversores en marzo. Jack Khattar, Presidente y CEO, representará a la empresa en estos eventos.
La empresa contará con un chat informal en la Barclays Global Healthcare Conference, que estará disponible a través de una transmisión en vivo de audio. Los inversores pueden acceder a la transmisión a través de la sección de Eventos y Presentaciones en el sitio web de Supernus en www.supernus.com. La grabación de la transmisión estará disponible durante 60 días después de la conferencia.
Los inversores interesados en reuniones con la dirección de Supernus durante estas conferencias deben comunicarse con los coordinadores de las respectivas conferencias para hacer los arreglos necesarios.
슈퍼너스 제약 (Nasdaq: SUPN), 중추 신경계(CNS) 질환을 전문으로 하는 생명공학 회사가 3월에 있을 투자자 회의에 참여할 것이라고 발표했습니다. 잭 카타르 사장 겸 CEO가 이 행사에서 회사를 대표합니다.
회사는 바클레이스 글로벌 헬스케어 컨퍼런스에서 화상 대담을 진행하며, 이는 생중계 오디오 웹캐스트를 통해 제공됩니다. 투자자들은 www.supernus.com의 이벤트 및 발표 섹션을 통해 웹캐스트에 접근할 수 있습니다. 웹캐스트 녹화는 회의 후 60일 동안 접근 가능합니다.
이 회의 중 슈퍼너스 경영진과의 미팅을 원하는 투자자는 각 회의의 조정자에게 연락하여 일정을 조율해야 합니다.
Supernus Pharmaceuticals (Nasdaq: SUPN), une entreprise biopharmaceutique spécialisée dans les maladies du système nerveux central (CNS), a annoncé sa participation à des conférences pour investisseurs prévues en mars. Jack Khattar, Président et CEO, représentera l'entreprise lors de ces événements.
L'entreprise participera à une discussion informelle lors de la Barclays Global Healthcare Conference, qui sera disponible en direct via un webcast audio. Les investisseurs peuvent accéder au webcast via la section Événements & Présentations du site web de Supernus à l'adresse www.supernus.com. L'enregistrement du webcast restera accessible pendant 60 jours après la conférence.
Les investisseurs intéressés par des réunions avec la direction de Supernus pendant ces conférences doivent contacter les coordinateurs des conférences respectives pour organiser les rencontres.
Supernus Pharmaceuticals (Nasdaq: SUPN), ein biopharmazeutisches Unternehmen, das sich auf Erkrankungen des zentralen Nervensystems (CNS) spezialisiert hat, hat seine Teilnahme an bevorstehenden Investorenkonferenzen im März angekündigt. Jack Khattar, Präsident und CEO, wird das Unternehmen bei diesen Veranstaltungen vertreten.
Das Unternehmen wird ein informelles Gespräch auf der Barclays Global Healthcare Conference präsentieren, das über einen Live-Audio-Webcast verfügbar sein wird. Investoren können auf den Webcast über den Bereich Veranstaltungen & Präsentationen auf der Website von Supernus unter www.supernus.com zugreifen. Die Aufzeichnung des Webcasts bleibt 60 Tage nach der Konferenz verfügbar.
Interessierte Investoren, die während dieser Konferenzen Meetings mit dem Management von Supernus anstreben, sollten sich an die jeweiligen Konferenzkoordinatoren wenden, um die Arrangements zu treffen.
- None.
- None.
ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences:
| Barclays Global Healthcare Conference | ||
| Date: | Tuesday, March 11, 2025 | |
| Fireside chat: | 12:30 p.m. ET | |
| Place: | Loews Miami Beach Hotel, Miami, Fla. | |
| Jefferies Biotech on the Beach Summit | ||
| Date: | Wednesday, March 12, 2025 | |
| Place: | Ritz-Carlton South Beach, Miami, Fla. | |
Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.
A live audio webcast of the Company’s fireside chat at the Barclays Global Healthcare Conference can be accessed here or by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company's website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
FAQ
When is Supernus Pharmaceuticals (SUPN) participating in the Barclays Global Healthcare Conference?
How can investors access Supernus (SUPN) fireside chat at the Barclays conference?
How long will the SUPN Barclays conference webcast replay be available?
How can investors arrange meetings with Supernus (SUPN) management during the March conferences?
